

Non-Small-Cell Lung Cancer Market Size Set for Rapid Expansion, Valued at USD 36.9 billion by 2031 | CAGR of 9.3%

The non-small cell lung cancer market grow at a CAGR of around 9.3% from 2021-2031.

PORTLAND, OR, UNITED STATES, June 10, 2026 /EINPresswire.com/ -- Allied Market Research published a report, titled, "[Global Non-Small-Cell Lung Cancer Market](#) by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), by Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global non-small cell lung cancer industry generated \$15.3 billion in 2021 and is anticipated to generate \$36.9 billion by 2031, witnessing a CAGR of 9.3% from 2022 to 2031.

Non-small cell lung cancer is caused when the cells present in the body grow at an uncontrolled rate, leading to the formation of a tumor. NSCLC has different stages based on its progression. STAGE IV is the final stage of the disease, which is marked by the spreading of tumors into others parts of body. The management of NSCLC in patients requires the use of different treatments, such as immunotherapy, targeted therapy, and chemotherapy.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

For more information, contact us at alliedmarketresearch@alliedmarketresearch.com

<https://www.alliedmarketresearch.com/request-sample/666>

For more information, contact us at alliedmarketresearch@alliedmarketresearch.com or visit our website at <https://www.alliedmarketresearch.com>. The report provides a detailed analysis of the market size, growth rate, and key players in the industry. It also includes a comprehensive list of companies operating in the market, along with their financial performance and market share. The report is a valuable resource for investors, analysts, and industry professionals looking to gain a deeper understanding of the non-small cell lung cancer market and its future prospects.

□□□□□□□□ □□□□□□ & □□□ □□□□□□□□, □□□□□□□□, □□□ □□□□ □□□□□□□□, □□□□□□□ □□□ □□□□□□□□□□□□□□ □□ □□□ □□□□□□ □□□□□□.

□□□ □□□-□□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□□□□

- F. Hoffmann-La Roche Ltd,
- Novartis AG,
- Pfizer Inc.,
- Astrazeneca,
- Eli Lilly and Company,
- Merck & Co., Inc.,
- Bristol-Myers Squibb Company,
- Celgene Corporation,
- Sanofi,
- Boehringer Ingelheim

□□□-□□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□□□□□□□□ □□□ □□ □□□□ □□□□□ □□ □□□□□□□□ □□□□□□□□, □□□□□□□□□□□□:

Based on type, the adenocarcinoma segment held the highest market share in 2021, accounting for nearly half of the global non small cell lung cancer market, and is estimated to maintain its leadership status throughout the forecast period, owing to rise in smoking on regular basis around the globe. However, the large cell carcinoma segment is projected to manifest the highest CAGR of 11.3% from 2022 to 2031, owing to the advancements in R&D activities.

Based on treatment type, the targeted therapy segment held the highest market share in 2021, accounting for more than half of the global non small cell lung cancer market, and is estimated to maintain its leadership status throughout the forecast period, owing to its potential to prevent the growth of malignant cells. However, the immunotherapy segment is projected to manifest the highest CAGR of 12.7% from 2022 to 2031, owing to constant investment in developing new products by the key players.

Based on distribution channel, the hospital pharmacy segment accounted for the largest share in 2021, contributing to more than two-thirds of the global non small cell lung cancer market, and is projected to maintain its lead position during the forecast period. This is owing to prevalence of non-small cell lung cancer diseases, such as adenocarcinoma and large cell carcinoma and increase in number of hospitalization of patients suffering with NSCLC. However, the online pharmacy segment is expected to portray the largest CAGR of 15.1% from 2022 to 2031, owing to constant focus of market players to establish their products on e-commerce sales channels along with increase in number of online platforms related to healthcare.

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for around two-fifths of the global non small cell lung cancer market, and is likely to

This press release can be viewed online at: <https://www.einpresswire.com/article/918632444>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.